Survival and patient-reported outcomes of real-world patients with high-risk stage II and stage III colon cancer after 3 versus 6 months of adjuvant CAPOX.

被引：0
|
作者：
Franken, Ingrid A.
van der Baan, Frederieke H.
Vink, Geraldine R.
May, Anne Maria
van Grevenstein, Wilhelmina M. U.
Koopman, Miriam
Roodhart, Jeanine
机构：
[1] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands
[2] Netherlands Comprehens Canc Org IKNL, Dept Res & Dev, Utrecht, Netherlands
[3] Julius Ctr Hlth Sci & Primary Care, Dept Epidemiol, Utrecht, Netherlands
[4] Univ Med Ctr Utrecht, Dept Surg Oncol, Utrecht, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3616
引用
收藏
页数：1
相关论文
共 50 条
  • [41] EFFECT OF ADJUVANT CHEMOTHERAPY ON SURVIVAL BENEFIT IN STAGE III COLON CANCER PATIENTS STRATIFIED BY AGE: A REAL-WORLD COHORT STUDY.
    Kawamura, H.
    Morishima, T.
    Sato, A.
    Honda, M.
    Miyashiro, I.
    DISEASES OF THE COLON & RECTUM, 2020, 63 (06) : E328 - E328
  • [42] Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: The efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.
    Sougklakos, Ioannis
    Boukovinas, Ioannis
    Xynogalos, Spyros
    Kakolyris, Stylianos
    Ziras, Nikolaos
    Vaslamatzis, Michael
    Athanasiadis, Athanasios
    Ardavanis, Alexandros
    Androulakis, Nikolaos E. M.
    Christopoulou, Athina
    Makrantonakis, Paris
    Bompolaki, Iliada
    Christofyllakis, Charalampos
    Kentepozidis, Nikolaos K.
    Emmanouilides, Christos E.
    Kouroussis, Charalambos
    Prinarakis, Efthimios
    Kalisperi, Ageliki
    Mavroudis, Dimitrios
    Georgoulias, Vassilis
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
    Sobrero, A.
    Grothey, A.
    Iveson, T.
    Labianca, R.
    Yoshino, T.
    Taieb, J.
    Maughan, T.
    Buyse, M.
    Andre, T.
    Meyerhardt, J.
    Shields, A. F.
    Souglakos, I
    Douillard, J-Y
    Cervantes, A.
    ANNALS OF ONCOLOGY, 2018, 29 (05) : 1099 - 1107
  • [44] Duration of FOLFOX adjuvant chemotherapy in high-risk stage II and stage III colon cancer with deficient DNA mismatch repair.
    Wu, Zehua
    Hu, Huabin
    Wang, Chao
    Huang, Yan
    Deng, Yanhong
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY ON SURVIVAL OF ELDERLY PATIENTS WITH HIGH RISK STAGE II COLON CANCER.
    Kim, M.
    Kim, C.
    Bae, S.
    Hur, H.
    Min, B.
    Baik, S.
    Lee, K.
    Kim, N.
    DISEASES OF THE COLON & RECTUM, 2013, 56 (04) : E215 - E215
  • [46] Three Versus Six Months of Adjuvant Oxaliplatin-Containing Chemotherapy for Patients With Stage III Colorectal Cancer: A Contemporary Real-World Analysis
    Krishnan, Tharani
    Leung, Emily
    Vasconcelos, Joao Paulo Solar
    Lim, Howard
    Loree, Jonathan M.
    Davies, Janine
    Gill, Karamjit
    Gill, Sharlene
    JCO ONCOLOGY PRACTICE, 2025, 21 (03)
  • [47] Outcomes of adjuvant chemotherapy (AC) in young (YP) and elderly patients (EP) with high-risk stage II colon cancer (CC)
    Kumar, Aalok
    Kennecke, Hagen F.
    Lim, Howard John
    Renouf, Daniel John
    Gill, Sharlene
    Woods, Ryan
    Speers, Caroline
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [48] Adjuvant chemotherapy (AC) outcomes in young (YP) and elderly patients (EP) with high-risk stage II colon cancer (CC)
    Kumar, Aalok
    Kennecke, Hagen F.
    Lim, Howard John
    Renouf, Daniel John
    Gill, Sharlene
    Woods, Ryan
    Speers, Caroline
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [49] Eligibility of real-world patients with stage II/III colorectal cancer (CRC) in adjuvant chemotherapy (AC) trials
    Batra, Atul
    Kong, Shiying
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [50] Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07
    Kim, Seung Tae
    Kim, Sun Young
    Lee, Jeeyun
    Yun, Seong Hyeon
    Kim, Hee Cheol
    Lee, Woo Yong
    Kim, Tae Won
    Hong, Yong Sang
    Lim, Seok-Byung
    Baek, Ji Yeon
    Oh, Jae Hwan
    Ahn, Joong Bae
    Shin, Sang Joon
    Han, Sae-Won
    Kim, Seong Geun
    Kang, Seok Yun
    Sym, Sun Jin
    Zang, Dae Young
    Kim, Yeul Hong
    Choi, In Sil
    Kang, Jung Hun
    Kim, Min-Ji
    Park, Young Suk
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (33) : 3868 - +
12345